Matches in SemOpenAlex for { <https://semopenalex.org/work/W3113307462> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W3113307462 endingPage "175883592097419" @default.
- W3113307462 startingPage "175883592097419" @default.
- W3113307462 abstract "Currently, 6-month oxaliplatin-based chemotherapy has been recommended as the preferred adjuvant treatment against high-risk stage 2 and stage 3 colon cancer patients.Record retrieval was conducted in PubMed, Web of Science, Cochrane Central Register of Controlled Trials, American Society of Clinical Oncology and European Society for Medical Oncology meeting libraries from inception to November 2019. Regarding survival and tolerability, randomized controlled trials comparing different adjuvant systemic regimens against high-risk stage 2 and stage 3 colon cancer were eligible. Disease-free survival was primary endpoint. Network calculation was based on a random-effects model, and relative ranking of each node was numerically indicated by p score.A total of 30 trials were included, corresponding to 54,109 patients. Regarding disease-free survival, none of the analyzed regimens displayed significant superiority against common comparator 6-month capecitabine plus oxaliplatin (XELOX), while 12-month [network hazard ratio (HR) 0.81 (0.60-1.10); 0.79 (0.57-1.10)] and 3-month XELOX [0.95 (0.86-1.04); 0.93 (0.83-1.05)] were top-ranking regimens showing non-inferiority among overall and stage 3 patients. Moreover, by pairwise meta-analysis, 3-month XELOX demonstrated significant superiority against 6-month XELOX among low-risk stage 3 patients [pairwise HR 0.78 (0.63-0.97)]. Concerning adverse events, 3-month oxaliplatin-based chemotherapy was significantly better than the 6-month counterpart with respect to peripheral sensory neuropathy, thrombocytopenia and fatigue. The 12-month capecitabine monotherapy failed to display non-inferiority among other major adverse events.The 3-month XELOX treatment could be an alternative option of the 6-month regimen among low-risk stage 3 patients. Among high-risk stage 3 patients, 6-month oxaliplatin-based regimens still seem more competitive. In addition, clinical application of 12-month capecitabine monotherapy should be cautious, despite its top rankings, especially among non-Asian countries." @default.
- W3113307462 created "2020-12-21" @default.
- W3113307462 creator A5039207540 @default.
- W3113307462 creator A5040777345 @default.
- W3113307462 creator A5054898933 @default.
- W3113307462 creator A5059393102 @default.
- W3113307462 creator A5067612393 @default.
- W3113307462 creator A5079375938 @default.
- W3113307462 date "2020-01-01" @default.
- W3113307462 modified "2023-10-17" @default.
- W3113307462 title "Comparative efficacy and tolerability of adjuvant systemic treatments against resectable colon cancer: a network meta-analysis" @default.
- W3113307462 cites W1990423062 @default.
- W3113307462 cites W2040557955 @default.
- W3113307462 cites W2088095316 @default.
- W3113307462 cites W2119938514 @default.
- W3113307462 cites W2162304120 @default.
- W3113307462 cites W2766346103 @default.
- W3113307462 cites W2794889098 @default.
- W3113307462 cites W2795004907 @default.
- W3113307462 cites W2796050472 @default.
- W3113307462 cites W2796242903 @default.
- W3113307462 cites W2911188335 @default.
- W3113307462 cites W2932666194 @default.
- W3113307462 cites W2951134875 @default.
- W3113307462 cites W2951173958 @default.
- W3113307462 cites W2967844938 @default.
- W3113307462 cites W2972815950 @default.
- W3113307462 cites W4211133582 @default.
- W3113307462 doi "https://doi.org/10.1177/1758835920974195" @default.
- W3113307462 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7739130" @default.
- W3113307462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33403014" @default.
- W3113307462 hasPublicationYear "2020" @default.
- W3113307462 type Work @default.
- W3113307462 sameAs 3113307462 @default.
- W3113307462 citedByCount "2" @default.
- W3113307462 countsByYear W31133074622021 @default.
- W3113307462 countsByYear W31133074622022 @default.
- W3113307462 crossrefType "journal-article" @default.
- W3113307462 hasAuthorship W3113307462A5039207540 @default.
- W3113307462 hasAuthorship W3113307462A5040777345 @default.
- W3113307462 hasAuthorship W3113307462A5054898933 @default.
- W3113307462 hasAuthorship W3113307462A5059393102 @default.
- W3113307462 hasAuthorship W3113307462A5067612393 @default.
- W3113307462 hasAuthorship W3113307462A5079375938 @default.
- W3113307462 hasBestOaLocation W31133074621 @default.
- W3113307462 hasConcept C121608353 @default.
- W3113307462 hasConcept C126322002 @default.
- W3113307462 hasConcept C143998085 @default.
- W3113307462 hasConcept C168563851 @default.
- W3113307462 hasConcept C197934379 @default.
- W3113307462 hasConcept C203092338 @default.
- W3113307462 hasConcept C207103383 @default.
- W3113307462 hasConcept C2777909004 @default.
- W3113307462 hasConcept C2778375690 @default.
- W3113307462 hasConcept C2780962732 @default.
- W3113307462 hasConcept C44249647 @default.
- W3113307462 hasConcept C526805850 @default.
- W3113307462 hasConcept C71924100 @default.
- W3113307462 hasConceptScore W3113307462C121608353 @default.
- W3113307462 hasConceptScore W3113307462C126322002 @default.
- W3113307462 hasConceptScore W3113307462C143998085 @default.
- W3113307462 hasConceptScore W3113307462C168563851 @default.
- W3113307462 hasConceptScore W3113307462C197934379 @default.
- W3113307462 hasConceptScore W3113307462C203092338 @default.
- W3113307462 hasConceptScore W3113307462C207103383 @default.
- W3113307462 hasConceptScore W3113307462C2777909004 @default.
- W3113307462 hasConceptScore W3113307462C2778375690 @default.
- W3113307462 hasConceptScore W3113307462C2780962732 @default.
- W3113307462 hasConceptScore W3113307462C44249647 @default.
- W3113307462 hasConceptScore W3113307462C526805850 @default.
- W3113307462 hasConceptScore W3113307462C71924100 @default.
- W3113307462 hasLocation W31133074621 @default.
- W3113307462 hasLocation W31133074622 @default.
- W3113307462 hasLocation W31133074623 @default.
- W3113307462 hasLocation W31133074624 @default.
- W3113307462 hasOpenAccess W3113307462 @default.
- W3113307462 hasPrimaryLocation W31133074621 @default.
- W3113307462 hasRelatedWork W1953161284 @default.
- W3113307462 hasRelatedWork W1981154820 @default.
- W3113307462 hasRelatedWork W1997133872 @default.
- W3113307462 hasRelatedWork W2008622172 @default.
- W3113307462 hasRelatedWork W2010928484 @default.
- W3113307462 hasRelatedWork W2029040122 @default.
- W3113307462 hasRelatedWork W2075077394 @default.
- W3113307462 hasRelatedWork W2081174487 @default.
- W3113307462 hasRelatedWork W2145753255 @default.
- W3113307462 hasRelatedWork W349909140 @default.
- W3113307462 hasVolume "12" @default.
- W3113307462 isParatext "false" @default.
- W3113307462 isRetracted "false" @default.
- W3113307462 magId "3113307462" @default.
- W3113307462 workType "article" @default.